IL162482A - Use of il6-r/il-6 chimera in the manufacture of a medicament for treatment of neuron loss - Google Patents

Use of il6-r/il-6 chimera in the manufacture of a medicament for treatment of neuron loss

Info

Publication number
IL162482A
IL162482A IL162482A IL16248204A IL162482A IL 162482 A IL162482 A IL 162482A IL 162482 A IL162482 A IL 162482A IL 16248204 A IL16248204 A IL 16248204A IL 162482 A IL162482 A IL 162482A
Authority
IL
Israel
Prior art keywords
chimera
manufacture
treatment
medicament
neuron loss
Prior art date
Application number
IL162482A
Other languages
Hebrew (he)
Inventor
Michel Revel
Shalom Haggiag
Judith Chebath
Alon Levy
Peilin Zhang
Original Assignee
Yeda Res & Dev
Michel Revel
Shalom Haggiag
Judith Chebath
Alon Levy
Peilin Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Michel Revel, Shalom Haggiag, Judith Chebath, Alon Levy, Peilin Zhang filed Critical Yeda Res & Dev
Priority to IL162482A priority Critical patent/IL162482A/en
Publication of IL162482A publication Critical patent/IL162482A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders.
IL162482A 2001-12-31 2004-06-13 Use of il6-r/il-6 chimera in the manufacture of a medicament for treatment of neuron loss IL162482A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL162482A IL162482A (en) 2001-12-31 2004-06-13 Use of il6-r/il-6 chimera in the manufacture of a medicament for treatment of neuron loss

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL14741201A IL147412A0 (en) 2001-12-31 2001-12-31 The use of il6r/il6 chimera in nerve cell regeneration
PCT/IL2002/001058 WO2003059376A1 (en) 2001-12-31 2002-12-31 The use of il6r/il6 chimera in nerve cell regeneration
IL162482A IL162482A (en) 2001-12-31 2004-06-13 Use of il6-r/il-6 chimera in the manufacture of a medicament for treatment of neuron loss

Publications (1)

Publication Number Publication Date
IL162482A true IL162482A (en) 2013-06-27

Family

ID=11075915

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14741201A IL147412A0 (en) 2001-12-31 2001-12-31 The use of il6r/il6 chimera in nerve cell regeneration
IL162482A IL162482A (en) 2001-12-31 2004-06-13 Use of il6-r/il-6 chimera in the manufacture of a medicament for treatment of neuron loss

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL14741201A IL147412A0 (en) 2001-12-31 2001-12-31 The use of il6r/il6 chimera in nerve cell regeneration

Country Status (8)

Country Link
US (1) US7824670B2 (en)
EP (1) EP1461066B1 (en)
JP (1) JP4685354B2 (en)
AU (1) AU2002361489B2 (en)
CA (1) CA2472203C (en)
ES (1) ES2535156T3 (en)
IL (2) IL147412A0 (en)
WO (1) WO2003059376A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2527847C (en) * 2003-06-12 2015-09-29 Yeda Research & Development Co. Ltd Enhancement of oligodendrocyte differentiation
IL157309A0 (en) 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
EP1784486B1 (en) * 2004-06-23 2011-10-05 TissueGene, Inc. Nerve regeneration
AU2006286149B2 (en) * 2005-08-29 2012-09-13 Technion Research And Development Foundation Ltd. Media for culturing stem cells
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
JP5749659B2 (en) * 2009-03-12 2015-07-15 ハーゼ インベストメンツ ウーゲー Bone morphogenetic protein 2 (BMP2) variant with reduced BMP antagonist sensitivity
US20120219535A1 (en) * 2009-10-02 2012-08-30 University Of Southern California Cranial neural crest stem cells and culture condition that supports their growth
CA2845198A1 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
WO2013184938A2 (en) * 2012-06-08 2013-12-12 Alkermes. Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
WO2020006469A1 (en) * 2018-06-29 2020-01-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating and reducing traumatic brain injury-associated impairments using sgp130
KR20230084470A (en) * 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 Improvement of immune cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987198A (en) * 1995-09-19 1997-03-31 Tosoh Corp Neurocyte extending agent
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL130586A0 (en) 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
WO2001076507A2 (en) * 2000-04-11 2001-10-18 The University Of Miami Use of oxygen carriers to improve grafted cell survival in neural transplantation
ATE324906T1 (en) * 2000-09-14 2006-06-15 Ares Trading Sa USE OF CHIMERIC IL6-IL6R IN HUNTINGTON'S DISEASE

Also Published As

Publication number Publication date
US20050220761A1 (en) 2005-10-06
AU2002361489B2 (en) 2008-05-08
ES2535156T3 (en) 2015-05-05
EP1461066A1 (en) 2004-09-29
US7824670B2 (en) 2010-11-02
JP4685354B2 (en) 2011-05-18
CA2472203A1 (en) 2003-07-24
AU2002361489A1 (en) 2003-07-30
WO2003059376A8 (en) 2003-10-09
JP2005514442A (en) 2005-05-19
WO2003059376A1 (en) 2003-07-24
CA2472203C (en) 2014-02-18
EP1461066B1 (en) 2015-02-25
IL147412A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
YU37602A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
YU30004A (en) Use of flibanserin in the treatment of sexual disorders
MXPA04003668A (en) Type 4 phosphodiesterase inhibitors and uses thereof.
CY2014005I1 (en) TOPICAL GEL DELIVERY SYSTEMS FOR THE THERAPEUTIC TREATMENT OF SKIN DISORDERS
WO2004014953A3 (en) Anti-myelin associated glycoprotein (mag) antibodies
BG66292B1 (en) Humanized antibodies that recognize beta amyloid peptide
WO2001030381A3 (en) Use of csf-1 inhibitors
HK1076737A1 (en) Use of ep4 receptor ligands in the manufacture of a medicament for the treatment of il-6 involved diseases ep4
IL162482A (en) Use of il6-r/il-6 chimera in the manufacture of a medicament for treatment of neuron loss
DE60143964D1 (en) DRUGS TO TREAT OSTEONE COSMETICS AND TO SUPPLY PATIENTS WITH RISK TO OSTEONE CRYOSIS
WO2003039539A3 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
IL147188A (en) Use of il6ril6 chimera for the manufacture of a medicament for neurological diseases
IL161310A0 (en) Use of a substance signaling through gp 130 in pns disorders
HK1073779A1 (en) The use of darifenacin and the salt thereof
PL373490A1 (en) Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
CA2388728A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
AU9184901A (en) Use of il-6r/il-6 chimera in huntington's disease
MXPA03008406A (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists.
WO2003000269A3 (en) Novel use for pde 10a inhibitors
EA200100876A2 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EXCESSIVE IL-12 PRODUCTION
ATE384133T1 (en) RETINOLIC ACID RECEPTOR BETA-2 AND GENE THERAPY VECTORS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
HUP0104619A3 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
AU2728301A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
WO2001079435A3 (en) A new polypeptide- human flavoprotein subunit 14 and the polynucleotide encoding it

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees